$317.92
-0.92-0.29%
At close: Jul 19, 6:05 PM EDT
$317.00
-0.92-0.29%
After Hours: Jul 19, 6:05 PM EDT
15 minutes delayed
Comments
Loading...
West Pharmaceutical Servs
WSTNYSE
West Pharmaceutical Servs (NYSE:WST) Stock, Analyst Ratings, Price Targets, Forecasts
West Pharmaceutical Services Inc has a consensus price target of $404.33 based on the ratings of 6 analysts. The high is $536 issued by Jefferies on February 7, 2024. The low is $250 issued by Deutsche Bank on December 14, 2022. The 3 most-recent analyst ratings were released by UBS, Keybanc, and Jefferies on February 16, 2024, February 13, 2024, and February 7, 2024, respectively. With an average price target of $460.33 between UBS, Keybanc, and Jefferies, there's an implied 44.80% upside for West Pharmaceutical Services Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Keybanc
Jefferies
Stephens & Co.
B of A Securities
1calculated from analyst ratings
Analyst Ratings for West Pharmaceutical Servs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/16/2024 | Buy Now | 17.95% | UBS | John Sourbeer | $400 → $375 | Maintains | Neutral | Get Alert |
| 02/13/2024 | Buy Now | 47.84% | Keybanc | Paul Knight | $440 → $470 | Maintains | Overweight | Get Alert |
| 02/07/2024 | Buy Now | 68.6% | Jefferies | David Windley | $323 → $536 | Upgrade | Hold → Buy | Get Alert |
| 10/27/2023 | Buy Now | 22.67% | Stephens & Co. | Jacob Johnson | $420 → $390 | Maintains | Overweight | Get Alert |
| 08/30/2023 | Buy Now | 38.4% | Keybanc | Paul Knight | $415 → $440 | Maintains | Overweight | Get Alert |
| 08/21/2023 | Buy Now | 30.54% | Keybanc | Paul Knight | $385 → $415 | Maintains | Overweight | Get Alert |
| 07/28/2023 | Buy Now | 21.1% | Keybanc | Paul Knight | $375 → $385 | Maintains | Overweight | Get Alert |
| 07/17/2023 | Buy Now | 32.11% | Stephens & Co. | Jacob Johnson | $400 → $420 | Maintains | Overweight | Get Alert |
| 06/16/2023 | Buy Now | 27.39% | B of A Securities | Derik De Bruin | $390 → $405 | Upgrade | Neutral → Buy | Get Alert |
| 04/11/2023 | Buy Now | 25.82% | Stephens & Co. | Jacob Johnson | $330 → $400 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/17/2023 | Buy Now | 17.95% | Keybanc | Paul Knight | $315 → $375 | Maintains | Overweight | Get Alert |
| 12/14/2022 | Buy Now | -21.36% | Deutsche Bank | Justin Bowers | → $250 | Initiates | → Hold | Get Alert |
| 12/02/2022 | Buy Now | -0.92% | Keybanc | Paul Knight | $350 → $315 | Maintains | Overweight | Get Alert |
| 11/30/2022 | Buy Now | -21.36% | UBS | John Sourbeer | → $250 | Initiates | → Neutral | Get Alert |
| 10/28/2022 | Buy Now | -21.36% | B of A Securities | Derik De Bruin | $385 → $250 | Downgrade | Buy → Neutral | Get Alert |
| 10/28/2022 | Buy Now | 10.09% | Keybanc | Paul Knight | $400 → $350 | Maintains | Overweight | Get Alert |
| 07/29/2022 | Buy Now | 8.52% | Stephens & Co. | Jacob Johnson | $330 → $345 | Maintains | Equal-Weight | Get Alert |
| 04/29/2022 | Buy Now | 28.96% | B of A Securities | Derik De Bruin | $475 → $410 | Maintains | Buy | Get Alert |
| 04/29/2022 | Buy Now | 25.82% | Keybanc | Paul Knight | $475 → $400 | Maintains | Overweight | Get Alert |
| 09/15/2021 | Buy Now | 61.99% | B of A Securities | Derik De Bruin | $450 → $515 | Maintains | Buy | Get Alert |
| 07/30/2021 | Buy Now | 25.82% | Stephens & Co. | Jacob Johnson | $360 → $400 | Maintains | Equal-Weight | Get Alert |
| 07/30/2021 | Buy Now | 49.41% | Keybanc | Paul Knight | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for West Pharmaceutical Servs (WST) stock?
The latest price target for West Pharmaceutical Servs (NYSE:WST) was reported by UBS on February 16, 2024. The analyst firm set a price target for $375.00 expecting WST to rise to within 12 months (a possible 18.30% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
The latest analyst rating for West Pharmaceutical Servs (NYSE:WST) was provided by UBS, and West Pharmaceutical Servs maintained their neutral rating.
When was the last upgrade for West Pharmaceutical Servs (WST)?
The last upgrade for West Pharmaceutical Services Inc happened on February 7, 2024 when Jefferies raised their price target to $536. Jefferies previously had a hold for West Pharmaceutical Services Inc.
When was the last downgrade for West Pharmaceutical Servs (WST)?
The last downgrade for West Pharmaceutical Services Inc happened on October 28, 2022 when B of A Securities changed their price target from $385 to $250 for West Pharmaceutical Services Inc.
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $400.00 to $375.00. The current price West Pharmaceutical Servs (WST) is trading at is $317.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.